(HealthDay News) — Genetic susceptibility to ovarian cancer does not modify the protective effect of frequent aspirin use on ovarian cancer risk, according to a study published in JAMA Network Open.
Researchers examined whether the association between frequent aspirin use and ovarian cancer is modified by susceptibility to ovarian cancer, which was assessed using a polygenic score (PGS). Individual-level data were pooled from 8 case-control studies between 1995 and 2009.
The analysis included 4476 patients with nonmucinous ovarian cancer and 6659 control participants. Frequent aspirin use was reported in 13% of cases and 15% of control participants.
Frequent aspirin use was associated with a reduced risk of nonmucinous ovarian cancer (odds ratio [OR], 0.87; 95% CI, 0.76-0.99), and associations did not differ by PGS categories (P >.05 for all).
There were similar associations between frequent aspirin use and ovarian cancer for individuals with a PGS less than the median (OR, 0.85; 95% CI, 0.70-1.02) and greater than the median (OR, 0.86; 95% CI, 0.74-1.01). However, there was no association for individuals in the highest quintile of the PGS (OR, 1.02; 95% CI, 0.80-1.30).
“Frequent aspirin use reduces the risk of nonmucinous ovarian cancer — including high-grade serous and endometrioid ovarian cancer — across most strata of genetic risk based on a PGS, including among individuals with a PGS greater than the median,” the study authors wrote.
Several authors disclosed financial ties to the biopharmaceutical industry.